A bromodomain-independent mechanism of gene regulation by the BET inhibitor JQ1: direct activation of nuclear receptor PXR
Nucleic Acids Research · 2024
DOI: 10.1093/nar/gkad1175 ↗Kurz gefasst
Fachartikel in der Zeitschrift Nucleic Acids Research, 2024. Verfasst von Andrew D Huber und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemical Biology and Therapeutics, St. Jude Children's Research Hospital, 262 Danny Thomas Place, Memphis, TN 38105, USA. Hauptthemen laut MEDLINE: Azepines, Pregnane X Receptor, Triazoles. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIGMS NIH HHS, NIH HHS, ALSAC.
Abstract (Originalsprache)
Bromodomain and extraterminal (BET) proteins are extensively studied in multiple pathologies, including cancer. BET proteins modulate transcription of various genes, including those synonymous with cancer, such as MYC. Thus, BET inhibitors are a major area of drug development efforts. (+)-JQ1 (JQ1) is the prototype inhibitor and is a common tool to probe BET functions. While showing therapeutic promise, JQ1 is not clinically usable, partly due to metabolic instability. Here, we show that JQ1 and the BET-inactive (−)-JQ1 are agonists of pregnane X receptor (PXR), a nuclear receptor that transcriptionally regulates genes encoding drug-metabolizing enzymes such as CYP3A4, which was previously shown to oxidize JQ1. A PXR-JQ1 co-crystal structure identified JQ1′s tert-butyl moiety as a PXR anchor and explains binding by (−)-JQ1. Analogs differing at the tert-butyl lost PXR binding, validating our structural findings. Evaluation in liver cell models revealed both PXR-dependent and PXR-independent modulation of CYP3A4 expression by BET inhibitors. We have characterized a non-BET JQ1 target, a mechanism of physiological JQ1 instability, a biological function of (−)-JQ1, and BET-dependent transcriptional regulation of drug metabolism genes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Chemical Biology and Therapeutics, St. Jude Children's Research Hospital, 262 Danny Thomas Place, Memphis, TN 38105, USA.
- Department of Structural Biology, St. Jude Children's Research Hospital, 262 Danny Thomas Place, Memphis, TN 38105, USA.
- Graduate School of Biomedical Sciences, St. Jude Children's Research Hospital, 262 Danny Thomas Place, Memphis, TN 38105, USA.
ORCID-Profile: Andrew D Huber, Wenwei Lin, Sergio C Chai, Taosheng Chen
Förderung
- NIGMS NIH HHS
- NIH HHS
- ALSAC
- National Institute of General Medical Sciences
- National Institutes of Health
- Biological and Environmental Research
- U.S. Department of Energy
Zitieren
APA
Huber, A. D., Poudel, S., Wu, J., Miller, D. J., Lin, W., Yang, L., Bwayi, M. N., Rimmer, M. A., Gee, R. R. F., Seetharaman, J., Chai, S. C., & Chen, T. (2024). A bromodomain-independent mechanism of gene regulation by the BET inhibitor JQ1: direct activation of nuclear receptor PXR. Nucleic Acids Research. https://doi.org/10.1093/nar/gkad1175
Vancouver
Huber AD, Poudel S, Wu J, Miller DJ, Lin W, Yang L, et al. A bromodomain-independent mechanism of gene regulation by the BET inhibitor JQ1: direct activation of nuclear receptor PXR. Nucleic Acids Research. 2024. doi:10.1093/nar/gkad1175
BibTeX
@article{Huber2024,
author = {Huber, Andrew D and Poudel, Shyaron and Wu, Jing and Miller, Darcie J and Lin, Wenwei and Yang, Lei and Bwayi, Monicah N and Rimmer, Mary Ashley and Gee, Rebecca R Florke and Seetharaman, Jayaraman and Chai, Sergio C and Chen, Taosheng},
title = {A bromodomain-independent mechanism of gene regulation by the BET inhibitor JQ1: direct activation of nuclear receptor PXR},
journal = {Nucleic Acids Research},
year = {2024},
doi = {10.1093/nar/gkad1175}
}
EUVIMED